Safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb

被引：0

作者：

Hamid, O. ^{[1
]}

Ros, W. ^{[2
]}

Thompson, J. A. ^{[3
]}

Hu-Lieskovan, S. ^{[4
]}

Eskens, F. A. L. M. ^{[5
]}

Diab, A. ^{[6
]}

Doi, T. ^{[7
]}

Wasser, J. ^{[8
]}

Spano, J-P. ^{[9
]}

Rizvi, N. A. ^{[10
]}

Angevin, E. ^{[11
]}

Chiappori, A. ^{[12
]}

Ott, P. A. ^{[13
]}

Ganguly, B. J. ^{[14
]}

Fleener, C. ^{[15
]}

Dell, V. ^{[16
]}

Liao, K. ^{[16
]}

Joh, T. ^{[16
]}

Chou, J. ^{[17
]}

El-Khoueiry, A. ^{[18
]}

机构：

[1] Angeles Clin & Res Inst, Med, Los Angeles, CA USA

[2] Netherlands Canc Inst, Amsterdam, Netherlands

[3] Univ Washington, Seattle Canc Care Alliance, Dept Med, Seattle, WA 98195 USA

[4] UCLA, Sch Med, Med, Los Angeles, CA USA

[5] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands

[6] MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX USA

[7] Natl Canc Ctr Hosp East, Med Oncol, Chiba, Japan

[8] Neag Comprehens Canc Ctr, UConn Hlth, Div Hematol & Med Oncol, Farmington, CT USA

[9] Grp Hosp Pitie Salpetriere, Med Oncol, Paris, France

[10] Columbia Univ, Med, New York, NY USA

[11] Gustave Roussy Inst Cancerol, Med, Villejuif, France

[12] Univ S Florida, H Lee Moffitt Canc Ctr, Med, Tampa, FL USA

[13] Dana Farber Canc Inst, Med, Boston, MA 02115 USA

[14] Pfizer Inc, Early Oncol Dev & Clin Res, San Francisco, CA USA

[15] Pfizer Inc, Early Oncol Dev & Clin Res, Groton, CT 06340 USA

[16] Pfizer Inc, Early Oncol Dev & Clin Res, La Jolla, CA USA

[17] Pfizer, Res & Dev, San Francisco, CA USA

[18] Univ Southern Calif, Med, Los Angeles, CA USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1142PD

引用

页数：1